ALS

AMLX LAWSUIT ALERT: Levi & Korsinsky Notifies Amylyx Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Retrieved on: 
Monday, February 26, 2024
Court, NEXT, ALS, Telephone, COST, Apoptosis, CLASS, Patient, LLP, Cryptocurrency

NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Amylyx Pharmaceuticals, Inc. ("Amylyx" or the "Company") (NASDAQ: AMLX) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Amylyx Pharmaceuticals, Inc. ("Amylyx" or the "Company") (NASDAQ: AMLX) of a class action securities lawsuit.
  • CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Amylyx investors who were adversely affected by alleged securities fraud between November 11, 2022 and November 8, 2023.
  • Follow the link below to get more information and be contacted by a member of our team:
    AMLX investors may also contact Joseph E. Levi, Esq.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

Retrieved on: 
Monday, February 26, 2024
Traffic barrier, ALS, SOD1, Neurocrine Biosciences, Therapy, Neurocrine, FXN, GBA1, AAV, Research, FA, Vaccine

The candidate combines a frataxin (FXN) gene replacement payload with an intravenously administered, blood-brain barrier penetrant, novel capsid derived from Voyager’s TRACER™ capsid discovery platform.

Key Points: 
  • The candidate combines a frataxin (FXN) gene replacement payload with an intravenously administered, blood-brain barrier penetrant, novel capsid derived from Voyager’s TRACER™ capsid discovery platform.
  • Selection of the development candidate triggered a $5 million milestone payment to Voyager, which the Company expects to receive in the first quarter of 2024.
  • Voyager is eligible to receive additional future development and commercialization milestone payments based on the further advancement of this program.
  • We believe our strategy to replace the defective frataxin gene could address the underlying disease etiology of FA.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Boeing, Brooge, Cassava, and Amylyx and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, February 26, 2024
Boeing, News, Fraud, Neurobiology of Aging, Apoptosis, Cassava Sciences, MAX, City University, P.C, ALS, Initiative, Cassava, AMX0035, Journal, IBD, Security (finance), Evercore, Amyotrophy, Alaska Airlines, BROG, BIA, Complaint, Safety, Biomarker, Crash, Amylyx Pharmaceuticals, Science, Prescription, Scientific misconduct, BBC World Service, Alzheimer's disease, FDA, Food, Data management, Investor's Business Daily, Gaping, Risk, Patient, Cognition, Defendant, Pharmaceutical industry

Its Commercial Airplanes Segment is a leading producer of commercial aircraft and offers a family of commercial jetliners including its 737 MAX.

Key Points: 
  • Its Commercial Airplanes Segment is a leading producer of commercial aircraft and offers a family of commercial jetliners including its 737 MAX.
  • Throughout the Class Period, Defendants continued to assure investors that Boeing was laser-focused on safety and quality.
  • These false and misleading statements caused Boeing stock to trade at artificially inflated prices during the Class Period.
  • Also, according to the filed complaint, it took a near disaster to expose this heightened safety risk.

AB Science announces that Health Canada has issued a Notice of Non-Compliance-Withdrawal (NON/w) for masitinib in ALS

Retrieved on: 
Monday, February 26, 2024
Bias, PFS, EMA, Function, ALS, Health Canada, ANCOVA, Progression-free survival, JTR, OS, Observation, Tracheotomy, Patient, Clinical trial, CIR, Drug, Science, CAFS, Rated R, Pharmaceutical industry

Health Canada stated that a Request for Reconsideration can be filed within 30 days of receiving the NON/w.

Key Points: 
  • Health Canada stated that a Request for Reconsideration can be filed within 30 days of receiving the NON/w.
  • The reconsideration process will re-examine, with new assessors, the decision based on information that was included in the original submission.
  • AB Science provided a methodologically justified new claim “patients with ALS prior to any loss of function”, where CAFS and Overall Survival (OS) are significantly improved.
  • Based on the supporting arguments and counterarguments outlined above, AB Science intends to submit a Request for Reconsideration.

AMLX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Amylyx Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Sunday, February 25, 2024
Court, ALS, Person, Food, Complaint, Apoptosis, AMX0035, Patient, Amyotrophy, Pharmaceutical industry

Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/AMLX .

Key Points: 
  • Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/AMLX .
  • The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP

Retrieved on: 
Friday, February 23, 2024
Fever, European Commission, EMA, ALS, Committee, MND, Myalgia, Intracranial pressure, BIIB, Cerebrospinal fluid, Pain, Hope, Biogen, European, SOD1, Arthralgia, Civil service commission, Biomarker, Fatigue, CHMP, AFL, European Medicines Agency, Protein, Disease, UZ Leuven, Mutation, Myelitis, Neurology, Aseptic meningitis, Research, Chronic pain, Vaccine

If authorized by the European Commission (EC), QALSODY will be the first treatment approved in the European Union to target a genetic cause of ALS, also known as motor neuron disease (MND).

Key Points: 
  • If authorized by the European Commission (EC), QALSODY will be the first treatment approved in the European Union to target a genetic cause of ALS, also known as motor neuron disease (MND).
  • “The CHMP’s positive opinion reinforces the impact QALSODY can have in SOD1-ALS and further demonstrates Biogen’s commitment to address the unmet needs of people living with ALS and neuromuscular diseases,” said Priya Singhal, M.D., M.P.H., Head of Development at Biogen.
  • Trends towards improvement in the physical abilities of participants who received QALSODY were seen compared to those who received placebo, as measured by the ALS Functional Ratings Scale-Revised (ALSFRS-R).
  • Serious neurologic events, including myelitis and/or radiculitis; papilledema and elevated intracranial pressure; and aseptic meningitis have also been reported.

Azimut and SOQUEM Deliver More Wide High-Grade Lithium Drill Intercepts on Galinée, James Bay Region, Quebec

Retrieved on: 
Friday, February 23, 2024
Well, Diamond, ALS, Property, Quartz, LIBS, LCT, Element, BTW, ICP, Anomaly, Lithium, Laboratory, Rare-earth element

LONGUEUIL, Quebec, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Azimut Exploration Inc. (“Azimut” or the “Company”) (TSXV: AZM) (OTCQX: AZMTF) is pleased to report additional assay results from the maiden 5,000-metre core drilling program on the Galinée Property (the “Property”) in the Eeyou Istchee James Bay region of Quebec, Canada. The previously reported results from the first hole (GAL23-001) include 2.48% Li2O over 72.7 m (see press release of January 9, 2024). Drilling will resume in March to accelerate the definition of the mineralized zone.

Key Points: 
  • As currently defined, the lithium-bearing zone on the Property has a strike length of 700 metres and trends roughly east-west.
  • The lithium-bearing intervals are related to spodumene pegmatite but may also include metric to multi-meter low grade sub-intervals of amphibolite.
  • At the current exploration stage, spodumene pegmatite mineralization roughly delineates a regional corridor 18 kilometres long by 1 kilometre wide.
  • Core samples are sent to ALS Laboratories in Val-d’Or (Quebec) for ICP multi-element analysis (laboratory codes: ME-MS61, ME-MS89L, ME-ICP82b).

Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates

Retrieved on: 
Thursday, February 22, 2024
ACT, ERP, Central nervous system, Dementia, Excitotoxicity, ALS, Research, MNDA, Pathology, Research and development, Inflammation, HGF, Conference, Society, Annual general meeting, Doctor of Philosophy, Frontiers, Biomarker, Administration, Clinical trial, Survival, Investment, Neuroprotection, Three-body problem, G&A, Athira Pharma, Lewy body, Insurance, Pharmaceutical industry

BOTHELL, Wash., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the year ended December 31, 2023, and reviewed recent pipeline and business updates.

Key Points: 
  • In December 2023, the Company announced encouraging results from the exploratory Phase 2 SHAPE clinical trial to evaluate fosgonimeton in patients with Parkinson's disease dementia and dementia with Lewy bodies.
  • In May 2023, Athira selected the 40 mg dose for further development and potential regulatory approval.
  • In January 2024, Athira completed enrollment of the LIFT-AD study, randomizing approximately 315 patients in the primary analysis population.
  • In December 2023, Athira announced encouraging results from the exploratory SHAPE Phase 2 clinical trial of fosgonimeton for the potential treatment of Parkinson's disease dementia and dementia with Lewy bodies.

Shareholders that lost money on Amylyx Pharmaceuticals, Inc. (AMLX) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More

Retrieved on: 
Thursday, February 22, 2024
Court, NEXT, ALS, Telephone, COST, Apoptosis, CLASS, Patient, LLP, Ursodoxicoltaurine, Cryptocurrency

NEW YORK, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Amylyx Pharmaceuticals, Inc. ("Amylyx" or the "Company") (NASDAQ: AMLX) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Amylyx Pharmaceuticals, Inc. ("Amylyx" or the "Company") (NASDAQ: AMLX) of a class action securities lawsuit.
  • Follow the link below to get more information and be contacted by a member of our team:
    AMLX investors may also contact Joseph E. Levi, Esq.
  • WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

Clene Reports Significant Survival Benefit With CNM-Au8® Treatment in ALS EAP Compassionate Use Programs

Retrieved on: 
Thursday, February 22, 2024
ACT, Massachusetts General Hospital, Mass, Master of Science, NINDS, Bangladesh Technical Education Board, Neuromuscular disease, ALS, CNM, Doctor of Philosophy, NIH, FDA, Record, Hospital, Risk, Natural history, EAPS, Multiple sclerosis, Safety, Data, Patient, Survival, Disease, Harvard Medical School, Columbia University, EAP, Mortality, DSM-IV codes, Pharmaceutical industry

CNM-Au8 30 mg treatment was well-tolerated, without a single serious adverse event attributed to CNM-Au8, and no significant safety findings reported.

Key Points: 
  • CNM-Au8 30 mg treatment was well-tolerated, without a single serious adverse event attributed to CNM-Au8, and no significant safety findings reported.
  • A pooled survival analysis of EAP participants treated with CNM-Au8 30 mg was compared to two independent datasets derived from PRO-ACT and the ALS/MND Natural History Consortium.
  • The EAP dataset was comprised of 256 participants with ALS of which 220 EAP participants had all baseline values available for matching.
  • The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital and Clene supported the first EAP (EAP01) launched in 2019.